Holen Sie sich die Stockscreener-App
1.15
2.68%
0.03
Handel nachbörslich:
1.14
-0.01
-0.87%
Schlusskurs vom Vortag:
$1.12
Offen:
$1.11
24-Stunden-Volumen:
119.37K
Relative Volume:
0.35
Marktkapitalisierung:
$39.54M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.14M
KGV:
-2.1296
EPS:
-0.54
Netto-Cashflow:
$-3.99M
1W Leistung:
+0.88%
1M Leistung:
-20.69%
6M Leistung:
-37.50%
1J Leistung:
-74.56%
1-Tages-Spanne:
$1.11
$1.19
1-Wochen-Bereich:
$1.07
$1.2399
52-Wochen-Spanne:
$1.07
$5.40
Telomir Pharmaceuticals Inc Stock (TELO) Company Profile
Firmenname
Telomir Pharmaceuticals Inc
Sektor
Branche
Telefon
786-396-6723
Adresse
100 SE 2ND ST, MIAMI
Compare TELO vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TELO
Telomir Pharmaceuticals Inc
|
1.15 | 38.51M | 0 | -16.14M | -3.99M | -0.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.92 | 116.41B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
785.51 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
811.45 | 50.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.76B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
353.92 | 38.40B | 4.98B | 69.60M | 525.67M | 0.5198 |
Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-21 | Eingeleitet | Rodman & Renshaw | Buy |
Telomir Pharmaceuticals Inc Aktie (TELO) Neueste Nachrichten
What are the risks of holding Telomir Pharmaceuticals IncChart Signals & Daily Growth Stock Investment Tips - baoquankhu1.vn
Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging - accessnewswire.com
Telomir Pharmaceuticals Highlights Preclinical Data for Telomir-1 - TipRanks
Experimental Telomir-Zn compound rebalances metals tied to cancer and aging - stocktitan.net
Telomir Pharmaceuticals Reports New Cellular Data on Epigenetic Modulation - TradingView
Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development - Hillsdale Daily News
Setup Watch: Can Telomir Pharmaceuticals Inc outperform under higher oil pricesJuly 2025 Selloffs & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
US Market Wrap: Is SIGA in a consolidation phasePortfolio Update Summary & Low Drawdown Investment Strategies - baoquankhu1.vn
Telomir Pharmaceuticals Inc. (TELO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is Telomir Pharmaceuticals Inc. a cyclical or defensive stockJuly 2025 Review & Growth Focused Stock Reports - mfd.ru
Insider Buy: How does Telomir Pharmaceuticals Inc compare to its peersRate Hike & Daily Profit Focused Screening - baoquankhu1.vn
Stock Analysis: How volatile is Telomir Pharmaceuticals Inc stockQuarterly Performance Summary & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Market Outlook: Is Telomir Pharmaceuticals Inc a cyclical or defensive stockWeekly Gains Report & Stepwise Trade Execution Plans - baoquankhu1.vn
Financial Survey: Telomir Pharmaceuticals (NASDAQ:TELO) versus electroCore (NASDAQ:ECOR) - Defense World
Gainers Report: What are the risks of holding Telomir Pharmaceuticals Inc2025 Stock Rankings & Daily Stock Trend Reports - baoquankhu1.vn
Will Telomir Pharmaceuticals Inc outperform small cap indexesJuly 2025 Review & Low Risk Entry Point Tips - baoquankhu1.vn
How does Telomir Pharmaceuticals Inc. compare to its peersJuly 2025 Weekly Recap & Technical Pattern Based Signals - bollywoodhelpline.com
Rodman & Renshaw initiates Telomir Pharma stock with Buy rating By Investing.com - Investing.com Canada
Aug Shorts: Is ImmuCell Corporation forming a bullish divergenceEarnings Overview Summary & Weekly Stock Breakout Alerts - baoquankhu1.vn
Telomir Pharmaceuticals Received Notice of Noncompliance - TradingView
Is Telomir Pharmaceuticals Inc. stock a top momentum playJuly 2025 Summary & Growth Focused Entry Point Reports - Улправда
Published on: 2026-01-10 12:17:57 - ulpravda.ru
Aug Movers: Why Telomir Pharmaceuticals Inc. stock is recommended by analystsGlobal Markets & Real-Time Market Trend Scan - ulpravda.ru
Is Telomir Pharmaceuticals Inc. stock in correction or buying zoneJuly 2025 Outlook & Advanced Swing Trade Entry Alerts - Улправда
Why retail investors favor Telomir Pharmaceuticals Inc. stockQuarterly Portfolio Summary & AI Forecast for Swing Trade Picks - Улправда
Trend Review: Why retail investors favor Telomir Pharmaceuticals Inc stockEarnings Growth Report & Step-by-Step Trade Execution Guides - Bộ Nội Vụ
Can Telomir Pharmaceuticals Inc. stock sustain revenue growthMerger & Acquisition Updates & Build Wealth With Expert Timing Advice - Улправда
Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models - The Florida Times-Union
How Telomir Pharmaceuticals Inc. stock reacts to inflationary pressuresLow Risk Investment Ideas & Minimal Investment Portfolio Growth - ulpravda.ru
Telomir Pharmaceuticals reports preclinical results for Telomir-1 in TNBC models - Investing.com Australia
Coinbase CEO Brian Armstrong Says His Biotech Company Is Working On 'Extending' Human Lifespan: Here Is How They Plan To Do It - Benzinga
Telomir Highlights Positive Preclinical Results for Telomir-1 in TNBC - TipRanks
Telomir Pharmaceuticals Reports Positive Preclinical Results for Telomir-1 - TradingView — Track All Markets
Experimental breast cancer drug slows aggressive tumors in animal tests - Stock Titan
Is Telomir Pharmaceuticals Inc. stock positioned for digital transformationOptions Trading Strategies & Start Investing With Free Smart Watchlists - bollywoodhelpline.com
Telomir Pharmaceuticals reports preclinical results for Telomir-1 in TNBC models By Investing.com - Investing.com Nigeria
Telomir Pharmaceuticals (NASDAQ:TELO) Shares Down 8.9% – Here’s What Happened - Defense World
Telomir Pharmaceuticals (NASDAQ:TELO) Shares Down 8.9%Here's What Happened - MarketBeat
Is Telomir Pharmaceuticals Inc stock oversold or undervaluedRisk Management & Weekly Hot Stock Watchlists - moha.gov.vn
Finanzdaten der Telomir Pharmaceuticals Inc-Aktie (TELO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.23%
1.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):